| NCT ID | NCT07121140 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Jefferson University |
| Condition | Hematologic Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-06-03 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-06-03 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Participants enrolled in the study will receive 1-5 units of blood products at home. Data on barriers to administration will be recorded. Surveys and qualitative interviews will be completed to better understand acceptability of the program.
Eligibility Criteria
Inclusion Criteria: * Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study: * Provide signed and dated informed consent form Willing to comply with all study procedures and be available for the duration of the study * Male or female, over the age of 18 * Must meet definition of transfusion dependence (require at least 2 blood product transfusions over a 28-day period) * Receive their cancer care at SKCCC * Have a history of blood product transfusions and NO history of transfusion reactions, * Live within a 30-mile range of the Center City SKCCC location. * Must be willing to allow people into the home Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in this study: * Patients who have a history of a transfusion reaction * Heart failure as defined by AHA stage C or NYHA Class II-IV * Non-English or Spanish speaking * Are unhoused * Are incarcerated * Have poor venous access * Diagnosis of Solid Tumor malignancy * Women who are pregnant
Contact & Investigator
Adam Binder, MD
PRINCIPAL INVESTIGATOR
Adam.Binder@jefferson.edu
Frequently Asked Questions
Who can join the NCT07121140 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07121140 currently recruiting?
Yes, NCT07121140 is actively recruiting participants. Contact the research team at Adam.Binder@jefferson.edu for enrollment information.
Where is the NCT07121140 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07121140 clinical trial?
NCT07121140 is sponsored by Thomas Jefferson University. The principal investigator is Adam Binder, MD at Adam.Binder@jefferson.edu. The trial plans to enroll 30 participants.